How can we improve the quality of Institute for Health Metrics and Evaluation (IHME)'s Global Burden of Disease #tuberculosis estimates? doi.org/10.1093/ije/dy… Now officially published and open access for all 🙂

Nice analysis by @aschwalbc of long-term data collected over decades by Prof Bothamley. Important to piece of puzzle of understanding TB in many low incidence settings, and perhaps how to improve clinical diagnosis and care.

Exciting to see this paper led by Katherine Horton out today in PNAS pnas.org/doi/10.1073/pn…! Putting years of work together to quantify the potential pathways people take following Mtb infection. Self-clearance, undulation, subclinical disease, something there for everyone. Enjoy!

Great to see this thought piece out! For so many TB drugs DST is still not widely available - to support clinicians, policymakers must provide pragmatic treatment recommendations for situations where resistance profile is unknown. So what should they do? erj.ersjournals.com/content/early/…

Very nice work - outlining what is already known about treating a new/not so new disease state. Important foundation for where we go next in TB treatment trials. Congrats team!

Come join us for a #PhD at London School of Hygiene & Tropical Medicine with Richard White, Tom Sumner, & Rebecca Clark 🎉 Help countries decide if and how they would introduce a new vaccine against #TB using mathematical modelling 🧮🧫 Deadline to apply is 23:59 (GMT) on 16 January 2024 mrc-lid.lshtm.ac.uk/2024-25-projec…

very nice ways to describe the problem, and work towards a solution. Congrats team, and Asad Zaidi for leading this work!

Excellent work to get this over the line - congrats Jon Emery and wider team. A beautiful analysis that follows the empirical data, providing another piece of the puzzle of subclinical disease.

New #Vaccine publication: Modelling new TB #vaccines in South Africa 🇿🇦 Vaccines were found to be impactful and cost-effective or cost-saving across a range of characteristics and delivery strategies CMMID LSHTM TB Centre Vaccine Centre London School of Hygiene & Tropical Medicine doi.org/10.1016/j.vacc…

LSHTM TB Centre Desmond Tutu Health Foundation Toyin Togun, PhD FFPH Dr Sedona Sweeney Rein Houben Prof Joy Lawn Linda-Gail Bekker Register for WTBD here ucl.ac.uk/tb/world-tb-day

5 weeks today: UCL-LSHTM World TB Day Symposium, Session 1 will be on 'Inclusivity and accessibility', with Samara Barnes, Kate Yorke, Lena Faust, Limakatso Lebina. Hybrid event, free and open to all. Pre-registration required. ucl.ac.uk/tb/world-tb-day #tuberculosis #WorldTBDay

TB is biosocial disease. Although an infectious disease, the drivers of TB incidence and mortality are largely socially determined. Biomedical interventions are absolutely necessary, but not sufficient to #EndTB

Precision matters Here we (Ryan Dinkele Digby Warner & I) comment on how aerobiology is pushing the boundaries of MTB transmission research highlighting the need for precise terminology to describe phenomena & facilitate scientific inference #WTBD2024 thelancet.com/journals/lanin…

Estimating the Potential Public Health Value of BCG Revaccination ✅ Just Accepted 🔓 Open Access ✍️ Rebecca Clark, LSHTM TB Modelling Group, Richard White, @tomscriba, Chathika Weerasuriya, @tomsumner49 bit.ly/3xpslZZ

We asked a range of key decision-makers what they need to know to about potential new vaccines The results were..... Alot, and WHO's Full Value of Vaccine Assessments framework helps But FVVAs could be even more useful Our new paper gives 3 ways FVVAs could be even better:

Weight bands like that in treatment strategy sound completely logical. In the #RATIONS trial, 35% adult household contacts in control arm and 39% in intervention arm were underweight.

Subclinical tuberculosis is ~half of prevalent TB, could make people sick and cause transmission So, it is crucial to understand whether new TB vaccines prevent subclinical TB and what it means for global impact Find out how more in our new paper in The Lancet Microbe

In our new short report in Journal of Infectious Diseases, we estimate that half of all Mtb transmission occurs before individuals would be expected to access healthcare - and 80% of this transmission is attributable to subclinical disease. bit.ly/4ddE9yn

Are pan-TB treatment regimens likely to drive the emergence of novel drug resistance? We investigated, in a new paper here wwwnc.cdc.gov/eid/article/30… with Emily Kendall Nick Menzies Richard White Ted Cohen Tess Ryckman London School of Hygiene & Tropical Medicine LSHTM TB Centre CMMID LSHTM TB Modelling Group